For instance, the discovery of Transmembrane Protease, Serine 2 gene (TMPRSS2) with the erythroblast R transformation gene (ERG) (TMPRSS2-ERG) fusions in over 50% of prostate cancers has enabled the stratification of patients and prediction of response to androgen deprivation therapies [4]. The gene discussed is TMPRSS2; the disease is Familial prostate cancer.